A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology group

被引：4
|
作者：
Miller, D. S.
Blessing, J. A.
Krasner, C. N.
Mannel, R. J.
机构：
[1] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Univ Oklahoma, Oklahoma City, OK USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.5524
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5524
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology
    Miller, David Scott
    Blessing, John A.
    Drake, Richard D.
    Higgins, Robert
    McMeekin, D. Scott
    Puneky, Louis V.
    Krasner, Carolyn N.
    GYNECOLOGIC ONCOLOGY, 2009, 115 (03) : 443 - 446
  • [2] A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group
    Miller, D. S.
    Blessing, J. A.
    Krasner, C. N.
    Drake, R. D.
    Higgins, R.
    McMeekin, D. S.
    Puneky, L. V.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
    Miller, David S.
    Blessing, John A.
    Krasner, Carolyn N.
    Mannel, Robert S.
    Hanjani, Parviz
    Pearl, Michael L.
    Waggoner, Steven E.
    Boardman, Cecelia H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) : 2686 - 2691
  • [4] Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group
    Miller, David Scott
    Blessing, John A.
    Bodurka, Diane C.
    Bonebrake, Albert J.
    Schorge, John O.
    GYNECOLOGIC ONCOLOGY, 2008, 110 (01) : 65 - 70
  • [5] Evaluation of pemetrexed (Alimta, Ly231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group
    Miller, D. S.
    Blessing, J. A.
    Bodurka, D. C.
    Bonebrake, A. J.
    Schorge, A. J.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S92 - S92
  • [6] A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study
    Dizon, Don S.
    Blessing, John A.
    Penson, Richard T.
    Drake, Richard D.
    Walker, Joan L.
    Johnston, Carolyn M.
    DiSilvestro, Paul A.
    Fader, Amanda Nickles
    GYNECOLOGIC ONCOLOGY, 2012, 125 (02) : 367 - 371
  • [7] A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study
    Coleman, R. L.
    Brady, W.
    McMeekin, D. S.
    Rose, P. G.
    Soper, J. T.
    Lentz, S. S.
    Hoffman, J. S.
    Shahin, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A gynecologic oncology group study
    Garcia, Agustin A.
    Sill, Michael W.
    Lankes, Heather A.
    Godwin, Andrew K.
    Mannel, Robert S.
    Armstrong, Deborah K.
    Carolla, Robert L.
    Liepman, Marcia K.
    Spirtos, Nick M.
    Fischer, Edgar G.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2012, 124 (03) : 569 - 574
  • [9] Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
    Schilder, Russell J.
    Brady, William E.
    Lankes, Heather A.
    Fiorica, James V.
    Shahin, Mark S.
    Zhou, Xun C.
    Mannel, Robert S.
    Pathak, Harsh B.
    Hu, Wei
    Alpaugh, R. Katherine
    Sood, Anil K.
    Godwin, Andrew K.
    GYNECOLOGIC ONCOLOGY, 2012, 127 (01) : 70 - 74
  • [10] A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study
    Monk, Bradley J.
    Kauderer, James T.
    Moxley, Katherine M.
    Bonebrake, Albert J.
    Dewdney, Summer B.
    Secord, Angeles Alvarez
    Ueland, Frederick R.
    Johnston, Carolyn M.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2018, 151 (03) : 422 - 427
12345